FLX Bio Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:FLX Bio Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11077
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
FLX Bio Inc (FLX Bio) is an immuno-oncology company that discovers and develops novel immuno-oncology agents. The company develops lead oral small molecule compound, FLX475, blocks a receptor called CCR4, found on nearly all human Treg cells that binds to secreted factors made in the tumor microenvironment. It also develops a pipeline of orally-available small-molecule drugs to activate the immune system and eradicate the cancer. The company has advanced into the clinic a dual-inhibitor drug that target FLT3 and CDK4 and 6 for the treatment of cancer. FLX Bio is headquartered in South San Francisco, California, the US.

FLX Bio Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
FLX Bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
FLX Bio Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
FLX Bio Raises USD60 Million in Series C Financing 10
FLX Bio Raises USD50 Million in Series B Financing 12
Partnerships 14
FLX Bio Enters into Agreement with Merck 14
Cofactor Genomics Enters into Agreement with FLX Bio 15
Licensing Agreements 16
FLX Bio Enters Into Licensing Agreement with Amgen 16
FLX Bio Inc – Key Competitors 17
FLX Bio Inc – Key Employees 18
FLX Bio Inc – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Corporate Communications 20
Feb 05, 2018: FLX Bio Names Michael Giordano As Board Director 20
Jan 03, 2018: FLX Bio Appoints Dirk G. Brockstedt, Ph.D., as Senior Vice President of Biology 21
May 31, 2017: FLX Bio Adds Distinguished Immuno-Oncology Experts to its Scientific Advisory Board 22
Clinical Trials 23
Sep 21, 2017: FLX Bio Selects Immuno-Oncology Clinical Candidate 23
Mar 31, 2017: FLX Bio to Present Poster at the American Association of Cancer Research Conference on its Lead Immuno-Oncology Program Targeting CCR4 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
FLX Bio Inc, Pharmaceuticals & Healthcare, Key Facts 2
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
FLX Bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
FLX Bio Inc, Deals By Therapy Area, 2012 to YTD 2018 8
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
FLX Bio Raises USD60 Million in Series C Financing 10
FLX Bio Raises USD50 Million in Series B Financing 12
FLX Bio Enters into Agreement with Merck 14
Cofactor Genomics Enters into Agreement with FLX Bio 15
FLX Bio Enters Into Licensing Agreement with Amgen 16
FLX Bio Inc, Key Competitors 17
FLX Bio Inc, Key Employees 18

List of Figures
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[FLX Bio Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • SBS Transit Ltd.:戦略・SWOT・企業財務分析
    SBS Transit Ltd. - Strategy, SWOT and Corporate Finance Report Summary SBS Transit Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Kaiser Foundation Health Plan Inc:企業の戦略的SWOT分析
    Kaiser Foundation Health Plan Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • AIA Group Limited:戦略・SWOT・企業財務分析
    AIA Group Limited - Strategy, SWOT and Corporate Finance Report Summary AIA Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Spineway SAS (ALSPW):企業の財務・戦略的SWOT分析
    Summary Spineway SAS (Spineway) is a medical device company that manufactures, designs, and commercializes surgical implants and instruments. The company offers products such as thoraco-lumbar, cervical, mini invasive products and other bio materials. Its thoraco-lumbar products include mont blanc d …
  • Kbc Bank Ireland Plc:企業の戦略・SWOT・財務分析
    Kbc Bank Ireland Plc - Strategy, SWOT and Corporate Finance Report Summary Kbc Bank Ireland Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Pudumjee Paper Products Limited:企業の戦略・SWOT・財務情報
    Pudumjee Paper Products Limited - Strategy, SWOT and Corporate Finance Report Summary Pudumjee Paper Products Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Nuance Communications Inc (NUAN):企業の財務・戦略的SWOT分析
    Nuance Communications Inc (NUAN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • C-Rad AB (CRAD B):企業の財務・戦略的SWOT分析
    Summary C-Rad AB (C-Rad) is a medical device company that develops, manufactures and markets advanced radiation therapy equipments. The company offers products and solutions for patient positioning, tumor localization, and radiation treatment systems. Its products include sentinel 4DCT, catalyst HD, …
  • Strongbridge Biopharma plc (SBBP):企業の財務・戦略的SWOT分析
    Summary Strongbridge Biopharma Plc (Strongbridge Biopharma), formerly Cortendo Plc is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases. The company’s marketed product KEVEYIS (dichlorphenamide) is indicated for the treatment of hypokalemic, hy …
  • Micro Focus International Plc (MCRO):企業の財務・戦略的SWOT分析
    Micro Focus International Plc (MCRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Omnicom Group Inc. (OMC):企業の財務・戦略的SWOT分析
    Omnicom Group Inc. (OMC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • British American Tobacco p.l.c.:企業の戦略・SWOT・財務情報
    British American Tobacco p.l.c. - Strategy, SWOT and Corporate Finance Report Summary British American Tobacco p.l.c. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • pSivida Corp (PSDV):製品パイプライン分析
    Summary pSivida Corp (pSivida) is a specialty pharmaceutical company that offers development of miniaturized, sustained-release drug delivery products and technologies. The company’s products include iluvien, retisert and durasert. Its durasert is an injectable, miniaturized, sustained-release drug …
  • Crrc Corporation Limited:企業の戦略・SWOT・財務分析
    Crrc Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary Crrc Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Group Five Ltd (GRF):企業の財務・戦略的SWOT分析
    Group Five Ltd (GRF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • EBTEC Corporation:企業の戦略・SWOT・財務分析
    EBTEC Corporation - Strategy, SWOT and Corporate Finance Report Summary EBTEC Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Alnylam Pharmaceuticals Inc (ALNY):製薬・医療:M&Aディール及び事業提携情報
    Summary Alnylam Pharmaceuticals Inc (Alnylam) is a biopharmaceutical company which discovers, develops and commercializes therapeutics based on Ribo Nucleic Acid interference (RNAi). The company offers a broad pipeline of investigational RNAi therapeutics in the areas of genetic medicines, hepatic i …
  • ERBA Molecular Ltd:企業の製品パイプライン分析2018
    Summary ERBA Molecular Ltd (ERBA Molecular), formerly Lumora Ltd, a subsidiary of Erba Diagnostics Mannheim GmbH, is a medical equipment company that offers innovative molecular diagnostics. The company provides technology that is used in medical diagnostics, agricultural, livestock and crops, food …
  • INRange Systems Inc:医療機器:M&Aディール及び事業提携情報
    Summary INRange Systems Inc (INRange) is a medical device company that develops and markets medication delivery systems. The company offers EMMA, a remote medication management system that provides individual unit dose control of medication dispensing, which is managed through a web-based scheduling …
  • Ferro Corp (FOE):企業の財務・戦略的SWOT分析
    Ferro Corp (FOE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆